Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 4/20 | 0.41 |
| ▸ | BTK | Q06187 | 13/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | NRAS | P01111 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23231145 | 1.00 | BRD4 (0.41) | BRD4ATAD2BTKCHEK1NRAS | |
| SCHEMBL17699876 | 1.00 | BRD4 (0.41) | BRD4ATAD2BTKCHEK1NRAS | |
| Trifluoroacetic Acid SCHEMBL29782734 | 0.90 | IRAK4 (0.40) | BRD4ATAD2BTKFLT3 | |
| SCHEMBL28165044 | 0.81 | BRD4 (0.43) | BRD4ATAD2BTKBPTF | |
| SCHEMBL28335791 | 0.81 | BRD4 (0.43) | BRD4ATAD2BTKBPTF | |
| SCHEMBL28164541 | 0.81 | BRD4 (0.43) | BRD4ATAD2BTKBPTF | |
| SCHEMBL19715346 | 0.79 | BTK (0.40) | BRD4ATAD2BTKCHEK1 | |
| SCHEMBL19715345 | 0.79 | BTK (0.40) | BRD4ATAD2BTKCHEK1 | |
| SCHEMBL17699570 | 0.77 | BTK (0.63) | BTKCHEK1 | |
| SCHEMBL29782460 | 0.77 | BTK (0.63) | BTKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-11623921-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-11 | — | — | US | disclosed |
| CN-110511209-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-15 | — | — | US | disclosed |
| CN-107108583-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3209656-B1 | INDOLE CARBOXAMIDES COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10604504-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| CN-110511209-A | It can be used as the indole carboxamides compound of kinase inhibitor | BRISTOL MYERS SQUIBB CO | 2019-11-29 | — | — | CN | disclosed |
| US-20190248760-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190119245-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3461821-A1 | INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9920031-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9802915-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170260160-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3209656-A1 | INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-08-30 | — | — | EP | disclosed |
| CN-107108583-A | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2017-08-29 | — | — | CN | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248760-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BRD4 3/4885ATAD2 2979/4885BTK 1/4885 |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BRD4 3/4885ATAD2 2979/4885BTK 1/4885 |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BRD4 3/4885ATAD2 2979/4885BTK 1/4885 |
| US-20170260160-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BRD4 3/4885ATAD2 2979/4885BTK 1/4885 |
| US-11623921-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | BRD4 3/4885ATAD2 2979/4885BTK 1/4885 |
| US-20190119245-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BRD4 3/4885ATAD2 2979/4885BTK 1/4885 |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BRD4 3/4885ATAD2 2979/4885BTK 1/4885 |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BRD4 3/4885ATAD2 2979/4885BTK 1/4885 |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BRD4 3/4885ATAD2 2979/4885BTK 1/4885 |
| US-10604504-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | BRD4 3/4885ATAD2 2979/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.